PUBLIKACJE

2013

  1. Augustin E, Pawłowska M, Polewska J, Potęga A, Mazerska Z. Modulation of CYP3A4 activity and induction of apoptosis, necrosis and senescence  by the anti-tumour imidazoacridinone C-1311 in human hepatoma cells. Cell Biology International 37: 109-120 (2013)
  2. Pawłowska M, Chu R, Fedejko-Kap B, Augustin E, Mazerska Z, Radomiska-Pandya A and Chambers T. Metabolic transformation of antitumor acridinone C-1305 but not C-1311 via selective cellular expression of UGT1A10 increases cytotoxic response: implications for clinical use. Drug Metabolism and Disposition 41:414-421(2013)
  3. Augustin E, Borowa-Mazgaj B, Kordalewska M, Kikulska A, Pawłowska M.  Overexpression of CYP3A4 enhances the cytotoxicity of the antitumor triazoloacridinone derivative C-1305 in CHO cells. Acta Pharmacologica Sinica, 34 (1), 146-156, 2013.
  4. Valerie NCK, Dziegielewska B, Hosing AS, Augustin E, Gray LS, Brautigan D, Larener JM, Dziegielewski J. Targeting of T-type calcium channels inhibits the Akt pro-survival pathway and promotes apoptosis in glioblastoma cells. Biochemical Pharmacology, 85:888-897, 2013.
  5. Nowicka AM, Kowalczyk A, Jarzębińska A, Donten M, Krysiński P, Stojek Z, Augustin E, Mazerska Z. Progress in targeting tumor cells by using drug-magnetic nanoparticles conjugate, Biomacromolecules, Doi: 10.1021/bm301868f. (2013)

2012

  1. Zabost E, Nowicka AM, Mazerska Z, Stojek Z.  Influence of temperature and interactions with ligands on dissociation of dsDNA and ligand-dsDNA complexes of various types of binding. An electrochemical study. Physical Chemistry Chemical Physics 14:3408-13 (2012)
  2. Wiśniewska A, Niemira M, Jagiełło K, Potęga A, Świst M, Henderson C, Skwarska A, Augustin E, Konopa J, Mazerska Z. Diminished toxicity of C-1748, 4-methyl 9-hydroxyethylamino-1-nitroacridine, compared with its demethyl analog, C-857, in HepG2 cells, corresponds to its resistance to metabolism. Biochemical Pharmacology 84:30-42 (2012)
  3. Fedejko-Kap B, Bratton SM, Finel M, Radominska-Pandya A and Mazerska Z. The role of human UDP—glucuronyltransferases in the biotransformation of the imidazo- and triazoloacridinone antitumor agents C-1305 and C-1311: highly selective substrates for UGT1A10. Drug Metabolism and Disposition 40:1736-1743 (2012)
  4. Beffinger M, Skwarska A. The role of FLT3 kinase as an AML therapy target. Current Pharmaceutical Design 18:  2758-2765 (2012)
  5. Polewska J. Autophagy – molecular mechanism, apoptosis and cancer. Postępy Higieny  i Medycyny Doświadczalnej 66: 921-936  (2012)
2011
  1. Paradziej-Lukowicz J, Skwarska A, Peszynska-Sularz G, Brillowska-Dąbrowska A, Konopa J. Anticancer imidazoacridinone C-1311 inhibits hypoxia inducible factor-1 alpha (HIF-1a), vascular endothelial growth factor (VEGF) and angiogenesis. Cancer Biology and Therapy 12: 586-597 (2011)
  2. Potęga A. Dabrowska E, Niemira M, Kot-Wasik A, Ronseaux S, Henderson CJ, Wolf R, Mazerska Z. The imidazoacridinone antitumor drug, C-1311, is metabolized by flavin monooxygenases but not by cytochrome P450s. Drug Metabolism and Disposition 39: 1423 – 1432 (2011)
  3. Fedejko-Kap B, Niemira M, Radominska-Pandya A, Mazerska Z. Flavin monooxygenases, FMO1 and FMO3, not cytochrome P450 isoenzymes, contribute to metabolism of antitumor triazoloacridinone, C-1305, in liver microsomes and HepG2 cells. Xenobiotica 41: 1044-1055 (2011)
  4. Pawłowska M, Augustin E. Expression systems of cytochrome P450 proteins in studies of drug metabolism in vitro. Postępy Higieny i Medycyny Doświadczalnej  65: 367-376 (2011)
  5. Fedejko B, Mazerska Z. UDP-glukuronylotransferazy – białka siateczki śródplazmatycznej. Struktura, mechanizm działania. Postępy Biochemii 57:41-48 (2011)
  6. Fedejko B, Mazerska Z. UDP-glukuronylotransferazy w metabolizmie detoksykacyjnym i aktywacyjnym związków endogennych oraz ksenobiotyków. Postępy Biochemii 57:49-62  (2011)
  7. Augustin E. Induction of apoptosis of human leukemia MOLT4 and HL60 cells by acyloksytriazoloacridinones – the new class of antitumor compounds. Postępy Polskiej Medycyny i Farmacji  1: 31-38 (2011)
2010
  1. Augustin E, Moś-Rompa A, Nowak-Ziatyk D, Konopa J. Antitumor 1-nitroacridine derivative C-1748, induces apoptosis, necrosis or senescence in human colon carcinoma HCT8 and HT29 cells. Biochemical Pharmacology, 79(9):1231-1241, 2010.
2009
  1. Nowicka AM, Zabost E, Klim B, Mazerska Z, Stojek Z, Interactions of dissolved dsDNA with intercalating drug by anodic voltamperometry and spectroscopy, Electroanalysis, 21, 52-60, 2009.
  2. Wiśniewska A, Mazerska Z. Izoenzymy cytochromu P450 w metabolizmie związków endo- i egzogennych. Postępy Biochemii, 55(3), 259-271, 2009.
  3. Wiśniewska A, Jagiełło K, Mazerska Z. Reduktaza NADPH: cytochrom P450 – nie tylko partner cytochromu P450. Postępy Biochemii, 55(3), 272-278, 2009.
  4. Niemira M, Wiśniewska A, Mazerska Z. Rola polimorfizmu i zróżnicowanej ekspresji genów cytochromów P450 w metabolizmie ksenobiotyków. Postępy Biochemii, 55(3), 279-289, 2009.
2007
  1. Skwarska A, Augustin E, Konopa J.: Sequential induction of mitotic catastrophe followed by apoptosis in human leukemia MOLT4 cells by imidazoacridinone C-1311. Apoptosis, 12 (12):2245-2257, 2007.
  2. Nowicka A, Zabost E, Donten M, Mazerska Z, Stojek Z. Spectroelectroanalytical properties of antitumor agent C-1311. Electroanalysis, 19/2-3: 214-219, 2007.
  3. Nowicka A, Zabost E, Donten M, Mazerska Z, Stojek Z. Electroanalytical and spectroscopic procedures for examination of interactions between double stranded DNA and intercalating drugs. Analytical and Bioanalytical Chemistry, 389 (6), 61931-1940, 2007.
  4. Nowicka AM, Zabost E, Donten M, Mazerska Z, Stojek Z. Electrooxidation of dissolved dsDNA backed by in situ UV-Vis spectroscopy, Bioelectrochemistry, 70, 440-445, 2007.
  5. Ashok B, Tadi K, Garikapaty V, Chen Y, Huang Q, Banerjee D, Konopa J, Tiwari R. Preclinical toxicological examination of a putative prostate cancer-specific 4-methyl-1-nitroacridine derivative in rodents. Anti-Cancer Drugs 18:87-94, 2007.
  6. Koba M, Konopa J. Interactions of antitumor triazoloacridinones with DNA. Acta Biochimica Polonica, 54(2):297-306, 2007.
  7. Wiśniewska A, Chrapkowska A, Kot-Wasik A, Konopa J, Mazerska Z. Metabolic transformations of antitumor imidazoacridinone, C-1311, with microsomal fractions of rat human liver enzymes. Acta Biochimica Polonica, 54, 831-838, 2007.
2006
  1. Polkowska Ż, Kozłowska K, Mazerska Z, Górecki T, Namieśnik J. Volatile organohalogen compounds in human urine: The effect of environmental exposure. Chemosphere, 62, 626-640, 2006.
  2. Nowicka A M, Zabost E, Donten M, Mazerska Z, Stojek Z. Electrooxidation of dissolved dsDNA backed by in situ UV-Vis spectroscopy. Bioelectrochemistry, 71, 126-131, 2006.
  3. Ashok B, Tadi K, Banerjee D, Konopa J, Iatropoulos M, Tiwari R. Pre-clinical toxicology and pathology of 9-(2’-hydroxyethylamino)-4-methyl-1-nitroacridine (C-1748), a novel anti-cancer agent in male Beagle dogs. Life Sciences, 79, 1334-1342, 2006.
  4. Augustin E, Moś-Rompa A, Skwarska A, Witkowski JM, Konopa J. Induction of G2/M phase arrest and apoptosis of human leukemia cells by potent antitumor triazoloacridinone C-1305. Biochemical Pharmacology, 72 (12), 1668-1679, 2006.
  5. Mazerska Z. Metabolism of chemical carcinogens, in Carcinogenic and anticarcinogenic food components. 37-66, ed. by A. Bartoszek et al., CRC Press, Boca Raton, Florida, 2006.